Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00040625 |
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Condition | Intervention | Phase |
---|---|---|
Mesothelioma |
Drug: Pemetrexed Drug: Cisplatin |
Phase II |
Study Type: | Expanded Access |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New Jersey | |
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. | |
Basking Ridge, New Jersey, United States | |
Brazil | |
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | |
Sao Paulo, Brazil | |
Brazil, RS | |
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | |
Porto Alegre, RS, Brazil | |
Egypt | |
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." | |
Cairo, Egypt | |
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | |
Cairo, Egypt | |
Saudi Arabia | |
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician | |
Jeddah, Saudi Arabia |
Study ID Numbers: | 6093, H3E-US-JMFE |
Study First Received: | July 2, 2002 |
Last Updated: | March 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00040625 |
Health Authority: | United States: Food and Drug Administration |
Folic Acid Pemetrexed Cisplatin |
Mesothelioma Adenoma Neoplasms, Glandular and Epithelial |
Antimetabolites Neoplasms by Histologic Type Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Neoplasms, Mesothelial Antineoplastic Agents Physiological Effects of Drugs |
Enzyme Inhibitors Folic Acid Antagonists Pharmacologic Actions Neoplasms Radiation-Sensitizing Agents Therapeutic Uses |